EUPRAXIA 6-K: Form 40-F Status, Contact Details and Exhibit 99.1

Rhea-AI Filing Summary

EUPRAXIA PHARMACEUTICALS INC. submitted a Form 6-K reporting its principal executive office address in Victoria, British Columbia, and indicated it files annual reports under Form 40-F. The report includes an exhibit: Exhibit 99.1, a press release dated September 22, 2025. The document is signed by Alex Rothwell, Chief Financial Officer, dated September 22, 2025. The filing appears to be a routine disclosure providing company contact details, the chosen annual-reporting form and a referenced press release.

Insights

Securities Compliance Analyst

TL;DR: Routine Form 6-K disclosing Form 40-F filing status, contact details and an attached press release; procedural compliance, not material news.

This filing confirms the registrant's chosen annual-reporting vehicle (Form 40-F) and supplies corporate contact information. The inclusion of Exhibit 99.1 (a press release dated September 22, 2025) indicates supplementary disclosure was furnished to the market. There are no financial statements, transaction details, or operational metrics in the provided text. From a compliance perspective, the report satisfies routine disclosure obligations but does not present new material facts requiring investor revaluation.

Corporate Governance Expert

TL;DR: Administrative filing that documents corporate address, reporting form and an attached press release; governance implications are minimal.

The document is signed by the CFO, demonstrating appropriate authorized execution. Designation of Form 40-F confirms the company follows the disclosure regime applicable to certain foreign issuers. No governance changes, executive appointments, or material transactions are reported in the provided content. This appears to be a standard disclosure packet rather than a governance event.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41923

EUPRAXIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant’s name)

201-2067 Cadboro Bay Road
Victoria, British Columbia, Canada V8R 5G4
Telephone: (250) 590-3968 
(Address and telephone number of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit
99.1		Press Release dated September 22, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	EUPRAXIA PHARMACEUTICALS INC.
Date: September 22, 2025	By:	/s/ Alex Rothwell
		Name: Alex Rothwell
		Title: Chief Financial Officer

FAQ

What reporting form does EPRX indicate it files for annual reports?

The filing indicates EUPRAXIA PHARMACEUTICALS INC. files annual reports under Form 40-F.

What exhibit is included with the 6-K for EPRX?

The report includes Exhibit 99.1, described as a press release dated September 22, 2025.

What is the principal executive office address listed for EPRX?

The principal executive office address is 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4 and telephone (250) 590-3968.

Who signed the Form 6-K for EUPRAXIA PHARMACEUTICALS INC.?

The filing was signed by Alex Rothwell, Chief Financial Officer, dated September 22, 2025.

Does this Form 6-K include financial statements or transaction details?

No. The provided content contains address details, reporting form selection and an exhibit reference; it does not include financial statements or transaction disclosures.